VV-14300

Asset

AAV vector expressing glucokinase injected into muscle to clear blood glucose

Stage: Phase 1
Modality: Gene therapy
Target: Insulin/IGF-1 signalling; 1
Indication: 2
Trials: 1
Developer

Indications

1

Type 1 diabetes
Phase 1, Recruiting, NCT07829302, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains4
Owner and partners1
Trials2
Evidence for its targets4
Competitors12
Aging relevance1
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.